PROJECTS
AVITHRAPID aims to establish a pipeline of early-stage drug candidates based on small molecules with demonstrated bioactivity against various viral targets. The project focuses on rapidly translating these into novel antiviral agents for emerging infectious diseases with pandemic potential. Additionally, it includes a Phase 2a clinical trial for a compound targeting the Zika virus.
AiChemist is a Marie Skłodowska-Curie Doctoral Network developing and benchmarking representation learning approaches to enhance accuracy and explainability in chemical predictions. Utilizing both public and proprietary data, the project aims to improve forecasts related to chemical reactions and toxicity, thereby advancing AI applications in chemistry.
DRUGREKINDLE
DRUGREKINDLE employs a clinically validated AI platform to repurpose existing pharmaceuticals and compounds that previously failed due to efficacy issues in clinical trials. The project aims to redefine drug repurposing, offering innovative therapeutic solutions through strategic vision and innovation.
LIGATE integrates computer-aided drug design solutions, leveraging current and future supercomputing capabilities. By combining tools like LiGen, GROMACS, and a new AI engine, the project enhances large dataset management to expedite the discovery of new treatments.
DIGITAL BIOMARKERS
Chelonia is developing an AI/ML platform that uses wearable devices and mobile technologies to capture physiological and behavioral data in real time. The goal is to identify and validate digital biomarkers for chronic diseases, enabling early detection, dynamic patient stratification, and personalized monitoring at population scale.
The AIDD project trains a new generation of scientists skilled in machine learning and drug discovery. By combining academic theoretical knowledge with industrial data, the initiative seeks to innovate pharmacological research through advanced AI methods, accelerating the development of new medications.
EXSCALATE4CoV utilized Europe's supercomputing resources to identify specific inhibitors against COVID-19. Through computational simulations and biochemical screenings, the project pinpointed promising molecules, such as raloxifene, for potential treatment of SARS-CoV-2.
REMEDi4ALL is an EU-funded initiative aimed at accelerating drug repurposing across Europe. The project establishes a comprehensive platform that supports the identification, testing, and validation of new therapeutic uses for existing medicines. By integrating scientific, regulatory, and patient-centric approaches, REMEDi4ALL seeks to streamline the development process, making treatments more accessible and cost-effective.
